Skip to main content
. Author manuscript; available in PMC: 2016 Dec 1.
Published in final edited form as: Mol Neurobiol. 2014 Oct 10;52(3):1119–1134. doi: 10.1007/s12035-014-8902-7

Fig. 3.

Fig. 3

Bryostatin-1 is a potent PKC modulator. It has been used to regulate PKC activity in a time-specific manner for multiple neural injury models. Protein concentrations were measured in the left prefrontal cortex 24 h after blast expsoure using western blot analysis. A significant difference between groups was observed for PKCα. Post-hoc comparison between control and single blast (*p<0.05), and between single blast and single blast + bryostatin-1 (##p<0.01) (a). A significant difference between groups was observed for PKCδ. Post-hoc comparison between control and single blast (**p<0.01), and control and single blast + bryostatin-1 (*p<0.05) (b). A significant difference between groups was observed for PKCε. Post-hoc comparison between control and single blast (*p<0.05), and between control and single blast + bryostatin-1 (**p<0.01) (c). Bryostatin-1 significantly decreased PKCα levels and increased PKCε levels when administered after blast exposure